GlassScriptPhysician profile
Jessica Weigand
NPI 1669911152
$24,220.20
in general payments reported to CMS, 2019-2025
24 companies · $9,890 in 2025
The $9,890 reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $671 · 2022: $1,026 · 2023: $6,448 · 2024: $6,185 · 2025: $9,890.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Food and Beverage: $5,072 · Travel and Lodging: $434 · Education: $17.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,000.00 |
| Food and Beverage | $5,071.98 |
| Travel and Lodging | $433.65 |
| Education | $17.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $18,877.53 | 2021-2025 | |
| Alkermes, INC. | $856.07 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Supernus Pharmaceuticals, INC. | $657.16 | 2023-2025 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $621.01 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $470.18 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $445.41 | 2021-2025 | Rexulti, Abilify Maintena, Brintellix |
| Janssen Pharmaceuticals, INC | $338.47 | 2022-2025 | Invega, Spravato |
| Axsome Therapeutics, INC. | $291.56 | 2022-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $252.70 | 2023-2025 | Ingrezza |
| Corium, LLC | $242.08 | 2022-2023 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $240.27 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Sunovion Pharmaceuticals INC. | $227.78 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $149.65 | 2022-2025 | Trintellix |
| Tris Pharma INC | $107.91 | 2025 | Dyanavel Xr |
| E.R. Squibb & Sons, L.L.C. | $90.65 | 2024-2025 | Cobenfy |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $77.42 | 2022-2023 | Perseris |
| Idorsia Pharmaceuticals US INC | $57.41 | 2023 | Quviviq |
| Collegium Pharmaceutical, INC. | $55.92 | 2025 | Jornay Pm |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $40.37 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $39.24 | 2025 | Spravato |
| Vanda Pharmaceuticals INC. | $30.68 | 2021 | |
| Ironshore Pharmaceuticals INC. | $17.85 | 2024 | |
| Sage Therapeutics, LLC | $16.66 | 2025 | Zurzuvae |
| Neos Therapeutics, LP | $16.22 | 2024 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Weigand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.